Encomenda rápida

VEGF / VEGFA / VEGF165 Anticorpo, Anticorpo monoclonal de coelho

    Folha de dadosAnálisesProdutos relacionadosProtocolos
    Humano VEGF-A Informação sobre produtos de anticorpos
    Imunogénio:Recombinant Human VEGF / VEGFA / VEGF165 protein (Catalog#11066-HNAB)
    Clone ID:105
    Tipo Ig:Rabbit IgG
    Concentração:
    Formulação:0.2 μm filtered solution in PBS
    Preparação:This antibody was obtained from a rabbit immunized with purified, recombinant Human VEGF / VEGFA / VEGF165 (rh VEGF / VEGFA / VEGF165; Catalog#11066-HNAB; P15692-4; Met 1-Arg 191).
    Other VEGF-A Antibody Products
    Immunochemical staining of human CCNF in human brain with rabbit polyclonal antibody (1 µg/mL, formalin-fixed paraffin embedded sections).
    VEGF/VEGFA Fundo

    Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) and VEGF-A, is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. It is a member of the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family and often exists as a disulfide-linked homodimer. VEGF-A protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, inhibiting apoptosis and tumor growth. VEGF-A protein is also a vasodilator that increases microvascular permeability, thus it was originally referred to as vascular permeability factor.

    Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

    Humano VEGF/VEGFA Referências
  • Woolard J. et al. (2004) VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 64(21): 7822-7835.
  • Jia SF, et al. (2008) VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells. J Exp Ther Oncol. 7(2): 89-97.
  • Cimpean AM, et al. (2008) Vascular endothelial growth factor A (VEGF A) as individual prognostic factor in invasive breast carcinoma. Rom J Morphol Embryol. 49(3): 303-8.
  • Hamdollah Zadeh MA, et al. (2008) VEGF-mediated elevated intracellular calcium and angiogenesis in human microvascular endothelial cells in vitro are inhibited by dominant negative TRPC6. Microcirculation. 15(7): 605-14.
  • Eisenach PA, et al. (2010) MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src. J Cell Sci. 123(Pt 23):4182-4193.
  • Claesson-Welsh L (2010) Gremlin: vexing VEGF receptor agonist. Blood. 116(18):3386-7.
  • Product nameProduct name
    Size / Price
    Catálogo: 11066-R105-50
    Preço de catálogo: 
    Preço:      (You Save: )
    Tamanho:
    50 µg
    100 µg
    Quantidade:+-
    DisponibilidadeIn Stock
    Acrescentar a carrinhoBulk Discount Requiry

    Datasheet & Documentation

    All information of our products is subject to change without notice. Please refer to COA enclosed in shipped package for the newest information.
    Tenha em atenção o seguinte: Todos os produtos destinam-se "A FINS EXCLUSIVOS DE INVESTIGAÇÃO E NÃO DEVEM SER UTILIZADOS PARA EFEITOS DE DIAGNÓSTICO OU TERAPÊUTICOS"